Chmielowski Bartosz
Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
J Skin Cancer. 2013;2013:423829. doi: 10.1155/2013/423829. Epub 2013 Apr 21.
Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent.
伊匹木单抗是一种全人源抗细胞毒性T淋巴细胞抗原4单克隆抗体，可增强抗肿瘤T细胞反应，在既往接受过治疗和未接受过治疗的不可切除III/IV期黑色素瘤患者中已显示出生存期延长。在包括脑转移患者在内的不同患者群体中也显示出生存获益。2011年，伊匹木单抗（每3周3mg/kg，共4剂）被美国食品药品监督管理局批准用于不可切除或转移性黑色素瘤。伊匹木单抗可诱导新的反应模式，为此已提出了免疫相关反应标准。免疫相关不良反应（irAE）很常见，但通常为低级别；更高级别可能很严重甚至危及生命。irAE通常可根据强调警惕性和及时干预的既定指南进行管理。该药物为转移性黑色素瘤提供了另一种治疗选择，不良事件管理指南有助于该新药的临床应用。
